2 weeks Ago By ABMN Staff
OraSure Technologies, Inc. ( NASDAQ:OSUR – Get Free Report ) was the target of a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 1,360,000 shares, a drop of 33.
3% from the August 31st total of 2,040,000 shares. Based on an average daily volume of 784,900 shares, the days-to-cover ratio is presently 1.7 days.
Wall Street Analysts Forecast Growth Several research firms have recently commented on OSUR. StockNews.com cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Saturday, August 17th.
Evercore ISI raised their price objective on shares of OraSure Technologies from $4.50 to $5.00 and gave the company an “in-line” rating in a research report on Wednesday, August 7th.
Three analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, OraSure Technologies presently has a consensus rating of “Hold” and a consensus price target of $6.
67. Read Our Latest Analysis on OSUR Institutional Trading of OraSure Technologies OraSure Technologies Stock Performance Shares of OSUR traded up $0.03 during trading hours on Friday, hitting $4.
29. 449,762 shares of the company were exchanged, compared to its average volume of 955,397. OraSure Technologies has a 52 week low of $3.
91 and a 52 week high of $8.45. The firm’s 50 day moving average is $4.
32 and its 200-day moving average is $4.86. The company has a market cap of $317.
28 million, a PE ratio of 14.30 and a beta of 0.05.
OraSure Technologies ( NASDAQ:OSUR – Get Free Report ) last released its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.03 earnings per share for the quarter.
The firm had revenue of $54.34 million during the quarter, compared to analyst estimates of $53.35 million.
OraSure Technologies had a net margin of 9.88% and a return on equity of 9.15%.
As a group, equities analysts forecast that OraSure Technologies will post -0.11 earnings per share for the current fiscal year. About OraSure Technologies ( Get Free Report ) OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally.
The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Read More Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter ..
